MedTrace Logo

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

NCT06730503 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-12-12

No results posted yet for this study

Summary

Immunotherapy has improved the prognosis of non-small cell lung cancer (NSCLC) patients, but about 80% of patients do not respond at all (primary resistance), and some patients initially respond to immunotherapy, later relapse and develop disease progression (acquired resistance).

So the objective of this research is to explore the sugar chain heterogeneity of primary and acquired resistance to immunotherapy in patients with NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Immune checkpoint inhibitor

Observe a situation before and after immunotherapy

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2027-10-31
Completion
2028-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730503 on ClinicalTrials.gov